Seeking Alpha hatchet job, page-186

I am glad you quoted my post.

The 206 subset that established the 60% mortality seems great.

But what did it prove? The primary endpoint was reduction in hospitalisation as a means to show underlying therapeutic effect. Instead, it proved that catching people with milder Disease potentially reduces their progression and mortality however - no reduction in hospitalisation?

So throw all that into a clinical trial and where do you start?

MSB cannot just keep on creating possible indications. it needs to prove its therapies work and that there is a market for them. ie approvals and sales.